GABRIEL SOSNE, MD
Medical Practice in Detroit, MI

8399412, Mar 19, 2013

Oct 5, 2007

12/444331

Gabriel Sosne - Oak Park MI, US
Michelle Wheater - Warren MI, US
Allan L. Goldstein - Washington DC, US

RegeneRx Biopharmaceuticals, Inc. - Rockville MD

A61K 38/17

514 166, 514 12

A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and/or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (Tβ4), an isoform of Tβ4, an N-terminal fragment of Tβ4, a C-terminal fragment of Tβ4, Tβ4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, Tβ4, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14, Tβ15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, β-actinin, acumentin, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a stimulating agent that stimulates production of an effective amount of the peptide agent in the subject, body, organ, tissue or cell.

2011002, Jan 27, 2011

May 7, 2010

12/775959

ALLAN L. GOLDSTEIN - WASHINGTON DC, US
GABRIEL SOSNE - OAK PARK MI, US

REGENERX BIOPHARMACEUTICALS, INC. - ROCKVILLE MD

A61K 38/00, A61K 9/00, A61P 27/02

424484, 514 208

Pain or irritation of the eyes, caused by injury due to dry eye syndrome, chemical burns or the like can be accompanied by corneal stromal edema. It has been discovered that administration of thymosin β4 and/or oxidized thymosin β4 to cornea in need of treatment of corneal stromal edema is a useful treatment for decreasing such corneal stromal edema.

2009013, May 21, 2009

Jun 19, 2006

11/917869

Gabriel Sosne - Oak Park MI, US
David Crockford - Newburyport MA, US
Allan L. Goldstein - Washington DC, US
Jack Finkelstein Jr. - Chevy Chase MD, US

REGENERX BIOPHARMACEUTICALS, INC. - Bethesda MD

A61K 38/16, A61K 38/08

514 12, 514 17

A pharmaceutical, ophthalmic or cosmetic combination or method utilizes a peptide agent include amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and further utilizes a quaternary ammonium salt, wherein the agent and the salt can be administered to a subject separately or together.

2008021, Sep 4, 2008

Jun 19, 2006

11/917883

Gabriel Sosne - Oak Park MI, US
Ewald Hannppel - Uttenreuth, DE
David Crockford - Newburyport MA, US
Allan L. Goldstein - Washington DC, US

REGENERX BIOPHARMACEUTICALS, INC. - Bethesda MD

A61K 38/08, A61K 38/00, A61K 38/22

514 12, 514 2, 514 16, 514 17

A composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and an ophthalmically acceptable carrier, an antimicrobially effective preservative, a tonicity agent for providing the composition with an ophthalmically acceptable tonicity, a comfort enhancing agent, at least one of an acidic or basic pH adjusting agent capable of adjusting pH of the composition to a desired ophthalmically acceptable pH level, and a buffer to substantially maintain the desired pH level.

2011017, Jul 14, 2011

Mar 13, 2009

12/933230

David Crockford - Newburyport MA, US
Christian B. Allan - Brookeville MD, US
Gabriel Sosne - Oak Park MI, US

REGENERX BIOPHARMACEUTICALS, INC. - Rockville MD

A61K 38/22, C07K 7/06, C07K 5/10, C07K 7/08, C07K 14/435, A61P 29/00, A61P 17/16

514 129, 530329, 530330, 530326, 530328, 530324

Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.

7268118, Sep 11, 2007

May 26, 2004

10/853505

Hynda K. Kleinman - Kensington MD, US
Allan L. Goldstein - Washington DC, US
Katherine M. Malinda - Millersville MD, US
Gabriel Sosne - Oak Park MI, US

United States of America as represented by The Secretary of Health - Washington DC

A61K 38/00, A61K 38/24

514 17, 514 12, 514 2, 530399, 930180

A composition with a polypeptide including amino acid sequence LKKTET [SEQ ID NO:1] or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.

2013019, Aug 1, 2013

Feb 4, 2013

13/758751

Christian B. ALLAN - Brookeville MD, US
Gabriel SOSNE - Oak Park MI, US

REGENERX BIOPHARMACEUTICALS, INC. - Rockville MD

C07K 14/575

514 97, 530326, 530329

Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.

2009002, Jan 22, 2009

Mar 9, 2007

11/715997

Hynda K. Kleinman - Kensington MD, US
Allan L. Goldstein - Washington DC, US
Katherine M. Malinda - Millersville MD, US
Gabriel Sosne - Oak Park MI, US

U.S.A. as represented by the Secretary of Health Office of Technology Transfer - Rockville MD

A61K 38/08, A61P 17/02

514 17

A method of treatment for skin, dermal or epidermal tissue utilizes a composition including an actin-binding polypeptide which may include amino acid sequence LKKTET [SEQ ID NO: 1] or a conservative variant thereof.